Iterum nabs speedy FDA antibiotic review, but follows in the footsteps of bankrupt biotechs

The FDA has accepted Iterum Therapeutics’ oral sulopenem for priority review in the treatment of certain uncomplicated urinary tract infections. Securing the speedy review positions Iterum to learn whether the FDA will approve the drug by July 25.